

Corrigendum to “Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer” [Eur Urol 2023;83:313–17] (European Urology (2023) 83(4) (313–317), (S0302283822025386), (10.1016/j.eururo.2022.07.023))

Gil-Jimenez, Alberto; van Dorp, Jeroen; Contreras-Sanz, Alberto; van der Vos, Kristan; Vis, Daniel J.; Braaf, Linde; Broeks, Annegien; Alcaraz, Antonio; Wessels, Lodewyk F.A.; More Authors

DOI

[10.1016/j.eururo.2023.03.002](https://doi.org/10.1016/j.eururo.2023.03.002)

Publication date

2023

Document Version

Final published version

Published in

European Urology

Citation (APA)

Gil-Jimenez, A., van Dorp, J., Contreras-Sanz, A., van der Vos, K., Vis, D. J., Braaf, L., Broeks, A., Alcaraz, A., Wessels, L. F. A., & More Authors (2023). Corrigendum to “Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer” [Eur Urol 2023;83:313–17] (European Urology (2023) 83(4) (313–317), (S0302283822025386), (10.1016/j.eururo.2022.07.023)). *European Urology*, 83(6), e165.
<https://doi.org/10.1016/j.eururo.2023.03.002>

Important note

To cite this publication, please use the final published version (if applicable).
Please check the document version above.

Copyright

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Takedown policy

Please contact us and provide details if you believe this document breaches copyrights.
We will remove access to the work immediately and investigate your claim.

Green Open Access added to TU Delft Institutional Repository

'You share, we take care!' - Taverne project

<https://www.openaccess.nl/en/you-share-we-take-care>

Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



Corrigendum

Corrigendum to “Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer” [Eur Urol 2023;83:313–17]

Alberto Gil-Jimenez^{a,b,1}, Jeroen van Dorp^{a,1}, Alberto Contreras-Sanz^c, Kristan van der Vos^a, Daniel J. Vis^{a,b}, Linde Braaf^d, Annegien Broeks^d, Ron Kerkhoven^e, Kim E.M. van Kessel^f, María José Ribal^g, Antonio Alcaraz^g, Lodewyk F.A. Wessels^{a,b,h}, Roland Seiler^{i,j}, Jonathan L. Wright^k, Lourdes Mengual^g, Joost Boormans^f, Bas W.G. van Rhijn^{l,m}, Peter C. Black^c, Michiel S. van der Heijden^{a,n,*}

^aDepartment of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; ^bOncode Institute, Utrecht, The Netherlands; ^cThe Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, Canada; ^dCore Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands; ^eCore Facility Genomics, Netherlands Cancer Institute, Amsterdam, The Netherlands; ^fDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands; ^gLaboratory and Department of Urology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Universitat de Barcelona, Barcelona, Spain; ^hFaculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, The Netherlands; ⁱDepartment of BioMedical Research, University of Bern, Bern, Switzerland; ^jDepartment of Urology, Hospital Center Biel, Biel, Switzerland; ^kDepartment of Urology, University of Washington School of Medicine, Seattle, WA, USA; ^lDepartment of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands; ^mDepartment of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany; ⁿDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands

The authors regret that the following statement regarding author contributions was missed:

Kristan van der Vos is currently a Scientific Editor for Cell Reports Medicine, which is published by Elsevier. Dr van der Vos was not involved in the peer-review process or editorial discussions about this manuscript.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.eururo.2022.07.023>

¹ These authors contributed equally to this work.

* Corresponding author. Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands, Tel. +31 20 5120 000.

E-mail address: ms.vd.heijden@nki.nl (M.S. van der Heijden).

<https://doi.org/10.1016/j.eururo.2023.03.002>

0302-2838/© 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

